VIMTALABSNSEVimta Labs Limited· PharmaceuticalsHighNeutral
Announced Thu, 17 Jul · 14:43 IST

Vimta Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue Growth 20pctPat Growth 25pctExceptional ItemResults View source PDF

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Vimta Labs posted strong Q1 FY26 results with revenue from operations rising about 30% year-on-year to Rs 975.64 million (vs Rs 748.76 million in Q1 FY25). Total income grew to Rs 993.13 million. Profit after tax from continuing operations jumped roughly 36% to Rs 188.94 million (vs Rs 139.05 million), while basic EPS stood at Rs 4.25 (adjusted for the recent 1:1 bonus issue). The statutory auditor issued an unmodified limited review report with no qualifications. Separately, the Board approved the change of cost auditor M/s Lavanya and Associates from a proprietorship to an LLP for FY25 and FY26, and granted 42,589 stock options to employees under the ESOP 2021 plan.

Likely market impact

Strong double-digit revenue and profit growth on a like-for-like continuing-operations basis is a clear positive for shareholders, supported by a clean auditor report. Per-share figures have been adjusted for the recent 1:1 bonus issue, so headline EPS comparisons should account for the doubled share count. Net impact is constructive on earnings momentum.